Enzalutamide: all 198 studies that test it

Page 2 of 2. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.

• Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and EnzalutamideCompletedNCT01946165Phase 2Results posted
• Study of Enzalutamide in Patients With Castration-resistant Prostate CancerCompletedNCT01942837Phase 2Results posted
• Enzalutamide in Patients With High-risk Prostate CancerCompletedNCT01927627Phase 2Results posted
• Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerCompletedNCT01889238Phase 2Results posted
• Tivozanib + Enzalutamide in Adv Prostate CancerTerminatedNCT01885949Phase 2Results posted
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate CancerCompletedNCT01664923Phase 2Results posted
• A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsCompletedNCT01650194Phase 2Results posted
• Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate CancerCompletedNCT01565928Phase 1Results posted
• A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100CompletedNCT01534052Phase 2Results posted
• A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone TherapyCompletedNCT01302041Phase 2Results posted
• A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerCompletedNCT01288911Phase 2Results posted
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate CancerCompletedNCT01212991Phase 3Results posted
• Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of EnzalutamideCompletedNCT01091103Phase 2Results posted
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based ChemotherapyCompletedNCT00974311Phase 3Results posted
• A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate CancerCompletedNCT00510718Phase 1Results posted
• Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate CancerCompletedNCT06312670Phase 2
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsTerminatedNCT05252390Phase 1
• Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerStatus unknownNCT05212857Phase 2
• Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPCWithdrawnNCT05191017Phase 1/2
• An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Active, not recruitingNCT05112965Phase 3
• EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPCTerminatedNCT05075577Phase 1/2
• A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid TumoursActive, not recruitingNCT05057013Phase 1/2
• Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate CancerTerminatedNCT05037500Phase 1
• HC-1119 Adjuvant Treatment for Hospitalized COVID-19 PatientsStatus unknownNCT04986176Phase 3
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCActive, not recruitingNCT04821622Phase 3
• Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.Active, not recruitingNCT04655365Phase 2
• ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04471974Phase 2
• Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1TerminatedNCT04456049Phase 2
• Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate CancerTerminatedNCT04409288Phase 3
• Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedNCT04381832Phase 1/2
• Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BCTerminatedNCT04142060Phase 2
• Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.Status unknownNCT04116775Phase 2
• A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate CancerCompletedNCT04094519Phase 1
• PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNAActive, not recruitingNCT04015622Phase 2
• Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side EffectsCompletedNCT03927391Phase 4
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.TerminatedNCT03869762Phase 2
• Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate CancerCompletedNCT03860987Phase 2
• HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)TerminatedNCT03850795Phase 3
• Combination of Entinostat and Enzalutamide in Advanced Prostate CancerTerminatedNCT03829930Phase 1
• A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug SwitchCompletedNCT03778047Phase 1
• A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its PharmacokineticsCompletedNCT03776968Phase 1
• A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.CompletedNCT03774056Phase 1
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
• Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT03751436Phase 1
• Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate CancerWithdrawnNCT03709550Phase 1/2
• Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.CompletedNCT03704519Phase 1
• Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by EnzalutamideActive, not recruitingNCT03700099Phase 2
• Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerCompletedNCT03674814Phase 1
• Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III StudyCompletedNCT03464201Phase 2
• Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen AblationCompletedNCT03297385Phase 2
• Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With DocetaxelCompletedNCT03295565Phase 2/3
• Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast CancerCompletedNCT03207529Phase 1
• Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate CancerStatus unknownNCT03196388Phase 2
• Combination Study of AZD5069 and Enzalutamide.TerminatedNCT03177187Phase 1/2
• Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate CancerStatus unknownNCT03124615Phase 2
• Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate CancerCompletedNCT03123978Phase 1
• A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.CompletedNCT03103724Phase 2
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerActive, not recruitingNCT03016741Phase 4
• Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast CancerWithdrawnNCT02929576Phase 3
• Enzalutamide Before Surgery in Treating Patients With Kidney CancerTerminatedNCT02885649Early Phase 1
• Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate CancerCompletedNCT02833883Phase 1
• Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving EnzalutamideCompletedNCT02815033Phase 2
• PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving EnzalutamideCompletedNCT02814968Phase 2
• Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast CancerActive, not recruitingNCT02750358Phase 2
• Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - EnzalutamideCompletedNCT02588001Not applicable
• Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate CancerCompletedNCT02532114Phase 1
• A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPCStatus unknownNCT02525068Phase 2
• Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone MetastasisCompletedNCT02507570Phase 2
• Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate CancerCompletedNCT02453009Phase 2
• Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate CancerActive, not recruitingNCT02446444Phase 3
• Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate CancerActive, not recruitingNCT02446405Phase 3
• Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSACompletedNCT02429193Phase 2
• Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or AibrateroneWithdrawnNCT02380313Phase 1
• Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.CompletedNCT02346578Phase 2
• Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate CancerCompletedNCT02339168Phase 1
• Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate CancerCompletedNCT02288936Phase 2
• Radium-223 in Combination With EnzalutamideCompletedNCT02225704Phase 2
• A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate CancerCompletedNCT02225093Phase 1
• Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT02207504Phase 1
• A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyWithdrawnNCT02159690Phase 2
• A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in MenCompletedNCT02138799Phase 1
• Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic CancerCompletedNCT02138383Phase 1
• A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in MenCompletedNCT02138162Phase 1
• Sequencing Abiraterone and Enzalutamide in mCRPCCompletedNCT02125357Phase 2
• Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate CancerCompletedNCT02125084Phase 1
• A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyCompletedNCT02124668Phase 2
• Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate CancerActive, not recruitingNCT02023463Phase 1
• Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and ItraconazoleCompletedNCT01913379Phase 1
• A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male SubjectsCompletedNCT01911741Phase 1
• Drug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesCompletedNCT01911728Phase 1
• A Study to Explore the Routes of Elimination of MDV3100CompletedNCT01911715Phase 1
• Relative Bioavailability Study of Enzalutamide in Prostate Cancer PatientsCompletedNCT01902251Phase 1
• Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control GroupCompletedNCT01901133Phase 1
• A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerWithdrawnNCT01663415Phase 2
• Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid TumorsCompletedNCT01362374Phase 1
• A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer PatientsCompletedNCT01284920Phase 1/2
• Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyActive, not recruitingNCT00268476Phase 2/3

← Enzalutamide overview